The Insulin Pump That Ditched Its Screen

"Time in range" is the gold standard metric in diabetes care; it measures how many hours per day your glucose stays in the safe zone of 70 to 180 mg/dL. Hitting 80% is considered excellent by endocrinologists.

At launch, the Flex will support two sensor options: MiniMed's own Simplera Sync and Abbott's Instinct sensor. That dual compatibility gives patients flexibility, which is increasingly important as the sensor market gets more crowded.

Who Gets It, and When

The clearance covers individuals aged 7 and older with type 1 diabetes and adults 18 and older with insulin-requiring type 2 diabetes. That's a meaningful scope, since type 2 patients represent a fast-growing segment of the pump market (projected to reach up to 40% of demand in coming years).

MiniMed plans to start a customer experience phase this spring with select existing users, followed by a broader commercial launch in summer 2026. And in a savvy move to prevent buyer's remorse, the company announced its MiniMed Forward Program: anyone who purchased a 780G system between February 18, 2026, and the Flex launch date can upgrade to the new device for $0. Zero dollars. That's the kind of gesture that builds brand loyalty in a market where switching costs are real.

A Three-Way Race Just Got More Interesting

The insulin pump market has turned into one of the most competitive corners of medtech. Three companies control the vast majority of U.S. sales, and each has a different playbook.

Insulet is a major force through its Omnipod line, a tubeless patch pump that sticks directly to the skin with no tubing at all. It's the cool kid in class: discreet, easy to use, and the most prescribed automated insulin delivery system in America.

Tandem holds roughly 35% of the U.S. market by volume with its t:slim pumps, which lean into touchscreens and software flexibility. The company is developing its own patch pump (called Sigi) to compete with Insulet on the tubeless front.

MiniMed, the market leader by global share, is playing catch-up on the "discreet and convenient" angle. The Flex is its answer. It's still a tubed pump (unlike Omnipod), but the dramatically smaller size and screenless design close the gap on lifestyle appeal. MiniMed also has a tubeless pump called the MiniMed Fit in its pipeline, though that device hasn't received FDA clearance yet.

The timing of this clearance is worth noting. It came just days after MiniMed's March 6 Nasdaq IPO (ticker: MMED), following its spinoff from Medtronic (which still owns about 90% of shares). Nothing says "we're ready to compete" like an FDA win in your first two weeks as a public company.

The Bigger Picture

The global insulin pump market sits at roughly $7 billion in 2025 and is growing at 8 to 10% per year. Analysts expect it to more than double by the mid-2030s, driven by rising diabetes rates and a generational shift in how patients think about their devices.

Today's insulin pump users, especially younger ones, don't just want something that works. They want something that fits their life. Something they don't have to explain at dinner parties or hide under baggy clothes. The entire market is moving toward smaller, smarter, and more connected devices.

MiniMed's Flex isn't the most radical product in the space (Insulet's fully tubeless design still wins on pure discretion). But it represents a company that heard its customers loud and clear: make the technology disappear, and more people will actually use it. In diabetes care, better adherence means better outcomes, fewer complications, and lower long-term costs.

The screen-free pump isn't just a gadget refresh. It's MiniMed betting that the future of medical devices looks a lot less like medical devices and a lot more like the tech already in your pocket.

America Invented CAR-T Therapy. Now It's Losing the Race.

CAR-T cell therapy was invented in America, but China now runs more clinical trials and enrolls patients twice as fast. With U.S. research funding under pressure and China's R&D spending pulling even, the global biotech balance of power is shifting faster than most people realize.